<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37373420</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Platelet-Derived Microparticles and Autoimmune Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10275</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241210275</ELocationID><Abstract><AbstractText>Extracellular microparticles provide a means of cell-to-cell communication and can promote information exchanges between adjacent or distant cells. Platelets are cell fragments that are derived from megakaryocytes. Their main functions are to stop bleeding, regulate inflammation, and maintain the integrity of blood vessels. When platelets are activated, they can perform related tasks by secreting platelet-derived microparticles that contain lipids, proteins, nucleic acids, and even organelles. There are differences in the circulating platelet levels in many autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid antibody syndrome, and Sjogren's syndrome. In this paper, the latest findings in the research field of platelet-derived microparticles are reviewed, including the potential pathogenesis of platelet-derived microparticles in various types of immune diseases, their potential as related markers, and for monitoring the progress and prognosis of disease treatment are expounded.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoshuai</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Blood Transfusion, Shengjing Hospital of China Medical University, Shenyang 110801, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qiushi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Blood Transfusion, Shengjing Hospital of China Medical University, Shenyang 110801, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021JH2/10300045</GrantID><Agency>Liaoning Science and Technology Program</Agency><Country/></Grant><Grant><GrantID>M0462</GrantID><Agency>Shengjing Hospital Clinical Study Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055252" MajorTopicYN="Y">Cell-Derived Microparticles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008533" MajorTopicYN="N">Megakaryocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diagnosis</Keyword><Keyword MajorTopicYN="N">autoimmune pathogenesis</Keyword><Keyword MajorTopicYN="N">autoimmune treatment</Keyword><Keyword MajorTopicYN="N">microparticles</Keyword><Keyword MajorTopicYN="N">platelet-derived microparticles</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37373420</ArticleId><ArticleId IdType="pmc">PMC10298940</ArticleId><ArticleId IdType="doi">10.3390/ijms241210275</ArticleId><ArticleId IdType="pii">ijms241210275</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang Y., Ma K.L., Gong Y.X., Wang G.H., Hu Z.B., Liu L., Lu J., Chen P.P., Lu C.C., Ruan X.Z., et al. Platelet Microparticles Mediate Glomerular Endothelial Injury in Early Diabetic Nephropathy. J. Am. Soc. Nephrol. 2018;29:2671&#x2013;2695. doi: 10.1681/ASN.2018040368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2018040368</ArticleId><ArticleId IdType="pmc">PMC6218868</ArticleId><ArticleId IdType="pubmed">30341150</ArticleId></ArticleIdList></Reference><Reference><Citation>Taleb R.S.Z., Moez P., Younan D., Eisenacher M., Tenbusch M., Sitek B., Bracht T. Proteomics for Biomarker Discovery: Methods and Protocols. Volume 1959. Humana Press; New York, NY, USA: 2019. Protein Biomarker Discovery Using Human Blood Plasma Microparticles; pp. 51&#x2013;64. Methods in Molecular Biology.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9164-8_4</ArticleId><ArticleId IdType="pubmed">30852815</ArticleId></ArticleIdList></Reference><Reference><Citation>Melki I., Tessandier N., Zufferey A., Boilard E. Platelet microvesicles in health and disease. Platelets. 2017;28:214&#x2013;221. doi: 10.1080/09537104.2016.1265924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2016.1265924</ArticleId><ArticleId IdType="pubmed">28102737</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon L., Suades R., Fuentes E., Palomo I., Padr&#xf3; T. Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis. Front. Pharmacol. 2016;7:293. doi: 10.3389/fphar.2016.00293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00293</ArticleId><ArticleId IdType="pmc">PMC5005978</ArticleId><ArticleId IdType="pubmed">27630570</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos C., Kallenberg C., Shoenfeld Y. Refractory disease in autoimmune diseases. Autoimmun. Rev. 2011;10:653&#x2013;654. doi: 10.1016/j.autrev.2011.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.04.026</ArticleId><ArticleId IdType="pubmed">21601657</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilat D. Introduction: Mechanisms of tissue injury in autoimmune diseases. Semin. Immunopathol. 2014;36:491&#x2013;493. doi: 10.1007/s00281-014-0446-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-014-0446-4</ArticleId><ArticleId IdType="pubmed">25168400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wang F.-S., Gershwin M.E. Human autoimmune diseases: A comprehensive update. J. Intern. Med. 2015;278:369&#x2013;395. doi: 10.1111/joim.12395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12395</ArticleId><ArticleId IdType="pubmed">26212387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf P. The Nature and Significance of Platelet Products in Human Plasma. Br. J. Haematol. 1967;13:269&#x2013;288. doi: 10.1111/j.1365-2141.1967.tb08741.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1967.tb08741.x</ArticleId><ArticleId IdType="pubmed">6025241</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber A.J., Johnson S.A. Platelet participation in blood coagulation aspects of hemostasis. Am. J. Pathol. 1970;60:19&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2032888</ArticleId><ArticleId IdType="pubmed">5426847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes F.G., Andrade A.C., Wolf M., Hochmann S., Krisch L., Maeding N., Regl C., Poupardin R., Ebner-Peking P., Huber C.G., et al. Synergy of Human Platelet-Derived Extracellular Vesicles with Secretome Proteins Promotes Regenerative Functions. Biomedicines. 2022;10:238. doi: 10.3390/biomedicines10020238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10020238</ArticleId><ArticleId IdType="pmc">PMC8869293</ArticleId><ArticleId IdType="pubmed">35203448</ArticleId></ArticleIdList></Reference><Reference><Citation>Botha J., Handberg A., Simonsen J.B. Lipid-based strategies used to identify extracellular vesicles in flow cytometry can be confounded by lipoproteins: Evaluations of annexin V, lactadherin, and detergent lysis. J. Extracell. Vesicles. 2022;11:e12200. doi: 10.1002/jev2.12200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jev2.12200</ArticleId><ArticleId IdType="pmc">PMC8971177</ArticleId><ArticleId IdType="pubmed">35362259</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhm F., Boilard E., Machlus K.R. Platelet Extracellular Vesicles. Arterioscler. Thromb. Vasc. Biol. 2020;41:87&#x2013;96. doi: 10.1161/ATVBAHA.120.314644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314644</ArticleId><ArticleId IdType="pmc">PMC7769913</ArticleId><ArticleId IdType="pubmed">33028092</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x17b;migrodzka M., Guzera M., Mi&#x15b;kiewicz A., Jagielski D., Winnicka A. The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression. Tumor Biol. 2016;37:14391&#x2013;14401. doi: 10.1007/s13277-016-5358-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-016-5358-6</ArticleId><ArticleId IdType="pmc">PMC5126185</ArticleId><ArticleId IdType="pubmed">27629289</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitz E., Pollitt A., Gitz-Francois J.J., AlShehri O., Mori J., Montague S., Nash G., Douglas M.R., Gardiner E., Andrews R.K., et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood. 2014;124:2262&#x2013;2270. doi: 10.1182/blood-2014-05-572818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-05-572818</ArticleId><ArticleId IdType="pmc">PMC4183985</ArticleId><ArticleId IdType="pubmed">25150298</ArticleId></ArticleIdList></Reference><Reference><Citation>Catani M.V., Savini I., Tullio V., Gasperi V. The &#x201c;Janus Face&#x201d; of Platelets in Cancer. Int. J. Mol. Sci. 2020;21:788. doi: 10.3390/ijms21030788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030788</ArticleId><ArticleId IdType="pmc">PMC7037171</ArticleId><ArticleId IdType="pubmed">31991775</ArticleId></ArticleIdList></Reference><Reference><Citation>Signorelli S.S., Conti G.O., Fiore M., Cangiano F., Zuccarello P., Gaudio A., Ferrante M. Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case&#x2013;Control Study. Vasc. Health Risk Manag. 2020;16:489&#x2013;495. doi: 10.2147/VHRM.S236286.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S236286</ArticleId><ArticleId IdType="pmc">PMC7705281</ArticleId><ArticleId IdType="pubmed">33273818</ArticleId></ArticleIdList></Reference><Reference><Citation>Custodio-Chabl&#xe9; S.J., Lezama R.A., Reyes-Maldonado E. Platelet activation as a trigger factor for inflammation and atherosclerosis. Cirug&#xed;a Cir. 2020;88:233&#x2013;243. doi: 10.24875/CIRUE.M20000119.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/CIRUE.M20000119</ArticleId><ArticleId IdType="pubmed">32116325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdi-Alamdarlou S., Ahmadi F., Shahbazi M.-A., Azadi A., Ashrafi H. Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple sclerosis. Mol. Biol. Rep. 2023;50:4675&#x2013;4686. doi: 10.1007/s11033-023-08322-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-023-08322-7</ArticleId><ArticleId IdType="pmc">PMC10078055</ArticleId><ArticleId IdType="pubmed">37022526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C., Bison E., Pontara E., Cattini M.G., Tonello M., Denas G., Pengo V. Platelet- and endothelial-derived microparticles in the context of different antiphospholipid antibody profiles. Lupus. 2022;31:1328&#x2013;1334. doi: 10.1177/09612033221118465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221118465</ArticleId><ArticleId IdType="pubmed">35968740</ArticleId></ArticleIdList></Reference><Reference><Citation>Thietart S., Rautou P.-E. Extracellular vesicles as biomarkers in liver diseases: A clinician&#x2019;s point of view. J. Hepatol. 2020;73:1507&#x2013;1525. doi: 10.1016/j.jhep.2020.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.07.014</ArticleId><ArticleId IdType="pubmed">32682050</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates A.G., Pink R.C., Erdbr&#xfc;gger U., Siljander P.R., Dellar E.R., Pantazi P., Akbar N., Cooke W.R., Vatish M., Dias-Neto E., et al. In sickness and in health: The functional role of extracellular vesicles in physiology and pathology in vivo: Part I: Health and Normal Physiology: Part I: Health and Normal Physiology. J. Extracell. Vesicles. 2022;11:e12151. doi: 10.1002/jev2.12151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jev2.12151</ArticleId><ArticleId IdType="pmc">PMC8765331</ArticleId><ArticleId IdType="pubmed">35041249</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaldivia M.T.K., McFadyen J.D., Lim B., Wang X., Peter K. Platelet-Derived Microvesicles in Cardiovascular Diseases. Front. Cardiovasc. Med. 2017;4:74. doi: 10.3389/fcvm.2017.00074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2017.00074</ArticleId><ArticleId IdType="pmc">PMC5702324</ArticleId><ArticleId IdType="pubmed">29209618</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatter F.A.P., Cioffi M., Hanna S.J., Castarede I., Caielli S., Pascual V., Matei I., Lyden D. Extracellular vesicle&#x2013; and particle-mediated communication shapes innate and adaptive immune responses. J. Exp. Med. 2021;218:e20202579. doi: 10.1084/jem.20202579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202579</ArticleId><ArticleId IdType="pmc">PMC8241538</ArticleId><ArticleId IdType="pubmed">34180950</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagel O., Walter E., Jurk K., Zahedi R.P. Taking the stock of granule cargo: Platelet releasate proteomics. Platelets. 2016;28:119&#x2013;128. doi: 10.1080/09537104.2016.1254762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2016.1254762</ArticleId><ArticleId IdType="pubmed">27928935</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcoux G., Duchez A.-C., Cloutier N., Provost P., Nigrovic P.A., Boilard E. Revealing the diversity of extracellular vesicles using high-dimensional flow cytometry analyses. Sci. Rep. 2016;6:35928. doi: 10.1038/srep35928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep35928</ArticleId><ArticleId IdType="pmc">PMC5081512</ArticleId><ArticleId IdType="pubmed">27786276</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael B.N.R., Kommoju V., Ganapathy C.K., Negi V.S. Characterization of cell-derived microparticles in synovial fluid and plasma of patients with rheumatoid arthritis. Rheumatol. Int. 2019;39:1377&#x2013;1387. doi: 10.1007/s00296-019-04337-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04337-1</ArticleId><ArticleId IdType="pubmed">31201512</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurenzana I., Trino S., Lamorte D., Girasole M., Dinarelli S., De Stradis A., Grieco V., Maietti M., Traficante A., Statuto T., et al. Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma. Int. J. Nanomed. 2021;16:3141&#x2013;3160. doi: 10.2147/IJN.S303391.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S303391</ArticleId><ArticleId IdType="pmc">PMC8114829</ArticleId><ArticleId IdType="pubmed">33994784</ArticleId></ArticleIdList></Reference><Reference><Citation>Latham S.L., Tiberti N., Gokoolparsadh N., Holdaway K., Couraud P.O., Grau G.E.R., Combes V. Immuno-analysis of microparticles: Probing at the limits of detection. Sci. Rep. 2015;5:16314. doi: 10.1038/srep16314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16314</ArticleId><ArticleId IdType="pmc">PMC4639787</ArticleId><ArticleId IdType="pubmed">26553743</ArticleId></ArticleIdList></Reference><Reference><Citation>Spakova T., Janockova J., Rosocha J. Characterization and Therapeutic Use of Extracellular Vesicles Derived from Platelets. Int. J. Mol. Sci. 2021;22:9701. doi: 10.3390/ijms22189701.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22189701</ArticleId><ArticleId IdType="pmc">PMC8468534</ArticleId><ArticleId IdType="pubmed">34575865</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui S., Yuan Y., Du C., Song P., Chen Y., Wang H., Fan Y., Armstrong D.G., Deng W., Li L. Comparison and Investigation of Exosomes Derived from Platelet-Rich Plasma Activated by Different Agonists. Cell Transplant. 2021;30:09636897211017833. doi: 10.1177/09636897211017833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09636897211017833</ArticleId><ArticleId IdType="pmc">PMC8138303</ArticleId><ArticleId IdType="pubmed">34006140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianazza E., Brioschi M., Baetta R., Mallia A., Banfi C., Tremoli E. Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics. Int. J. Mol. Sci. 2020;21:4541. doi: 10.3390/ijms21124541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21124541</ArticleId><ArticleId IdType="pmc">PMC7352998</ArticleId><ArticleId IdType="pubmed">32630608</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;ger J.L., Jougleux J.-L., Savadogo F., Pichaud N., Boudreau L.H. Rapid isolation and purification of functional platelet mitochondria using a discontinuous Percoll gradient. Platelets. 2019;31:258&#x2013;264. doi: 10.1080/09537104.2019.1609666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2019.1609666</ArticleId><ArticleId IdType="pubmed">31057000</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosi&#x144;ska J., &#x141;ukasik M., Kozubski W. The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles. Cardiovasc. Drugs Ther. 2017;31:627&#x2013;644. doi: 10.1007/s10557-017-6757-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-017-6757-7</ArticleId><ArticleId IdType="pmc">PMC5730634</ArticleId><ArticleId IdType="pubmed">29164426</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Liang Y., Xu X., Xia J., Wen C., Zhang P., Duan L. Blood cell-derived extracellular vesicles: Diagnostic biomarkers and smart delivery systems. Bioengineered. 2021;12:7929&#x2013;7940. doi: 10.1080/21655979.2021.1982320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1982320</ArticleId><ArticleId IdType="pmc">PMC8806567</ArticleId><ArticleId IdType="pubmed">34622717</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks J.A. Rheumatoid Arthritis. Ann. Intern. Med. 2019;170:ITC1&#x2013;ITC16. doi: 10.7326/AITC201901010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC201901010</ArticleId><ArticleId IdType="pubmed">30596879</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta S., Nakagomi D., Kobayashi Y., Hiraguri M., Sugiyama T., Amano K., Umibe T., Kono H., Kurasawa K., Kita Y., et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis. JAMA. 2021;325:2178&#x2013;2187. doi: 10.1001/jama.2021.6615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.6615</ArticleId><ArticleId IdType="pmc">PMC8170547</ArticleId><ArticleId IdType="pubmed">34061144</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal O., Sahel N., Saouab R., El Q.M., Zaizaa M., El K.I., Rkiouak A., Hammi S., Sekkach Y. Fatal Sys-temic Vasculitis Associated with Chronic Active Epstein-Barr Virus Infection. Mo. Med. 2021;118:226&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8210988</ArticleId><ArticleId IdType="pubmed">34149082</ArticleId></ArticleIdList></Reference><Reference><Citation>Catrina A., Krishnamurthy A., Rethi B. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. RMD Open. 2021;7:e001228. doi: 10.1136/rmdopen-2020-001228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001228</ArticleId><ArticleId IdType="pmc">PMC8006837</ArticleId><ArticleId IdType="pubmed">33771834</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafaro G., Bartoloni E., Alunno A., Gerli R. Platelets: A potential target for rheumatoid arthritis treatment? Expert Rev. Clin. Immunol. 2018;15:1&#x2013;3. doi: 10.1080/1744666X.2019.1544071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2019.1544071</ArticleId><ArticleId IdType="pubmed">30392437</ArticleId></ArticleIdList></Reference><Reference><Citation>Boilard E., Nigrovic P.A., Larabee K., Watts G.F.M., Coblyn J.S., Weinblatt M.E., Massarotti E.M., Remold-O&#x2019;donnell E., Farndale R.W., Ware J., et al. Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production. Science. 2010;327:580&#x2013;583. doi: 10.1126/science.1181928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1181928</ArticleId><ArticleId IdType="pmc">PMC2927861</ArticleId><ArticleId IdType="pubmed">20110505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S., Cavanagh B.L., Harrington R., Ahmad M., Kearns G., Meaney S., Wynne C. A Novel Pool of Microparticle Cholesterol Is Elevated in Rheumatoid Arthritis but Not in Systemic Lupus Erythematosus Patients. Int. J. Mol. Sci. 2020;21:9228. doi: 10.3390/ijms21239228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21239228</ArticleId><ArticleId IdType="pmc">PMC7730612</ArticleId><ArticleId IdType="pubmed">33287382</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Carrio J., Alperi-L&#xf3;pez M., Lopez-Suarez P., Alonso-Castro S., Carro-Esteban S.R., Ballina-Garcia F.J., Suarez-Diaz A.M. Altered profile of circulating microparticles in rheumatoid arthritis patients. Clin. Sci. 2014;128:437&#x2013;448. doi: 10.1042/CS20140675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20140675</ArticleId><ArticleId IdType="pubmed">25369551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu J., Gu Y., Tan S.-L., Narula S., DeMartino J.A., Liao C. Bruton&#x2019;s Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunol. Lett. 2013;150:97&#x2013;104. doi: 10.1016/j.imlet.2012.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2012.12.007</ArticleId><ArticleId IdType="pubmed">23266841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloutier N., Tan S., Boudreau L.H., Cramb C., Subbaiah R., Lahey L., Albert A., Shnayder R., Gobezie R., Nigrovic P.A., et al. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: The microparticle-associated immune complexes. EMBO Mol. Med. 2012;5:235&#x2013;249. doi: 10.1002/emmm.201201846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201846</ArticleId><ArticleId IdType="pmc">PMC3569640</ArticleId><ArticleId IdType="pubmed">23165896</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Du R., Xing W., Chen X., Wan J., Wang S., Xiong L., Nandakumar K.S., Holmdahl R., Geng H. Platelets derived citrullinated proteins and microparticles are potential autoantibodies ACPA targets in RA patients. Front. Immunol. 2023;14:1084283. doi: 10.3389/fimmu.2023.1084283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1084283</ArticleId><ArticleId IdType="pmc">PMC9902922</ArticleId><ArticleId IdType="pubmed">36761728</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovic A., Veselinovic M., Zong Y., Jakovljevic V., Pruner I., Antovic A. Increased Expression of Extracellular Vesicles Is Associated With the Procoagulant State in Patients With Established Rheumatoid Arthritis. Front. Immunol. 2021;12:718845. doi: 10.3389/fimmu.2021.718845.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.718845</ArticleId><ArticleId IdType="pmc">PMC8358654</ArticleId><ArticleId IdType="pubmed">34394126</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar-Vesga J., Grajales C., Burbano C., Vanegas&#x2013;Garc&#xed;a A., Mu&#xf1;oz&#x2013;Vahos C.H., V&#xe1;squez G., Rojas M., Casta&#xf1;o D. Platelet-derived microparticles generated in vitro resemble circulating vesicles of patients with rheumatoid arthritis and activate monocytes. Cell. Immunol. 2018;336:1&#x2013;11. doi: 10.1016/j.cellimm.2018.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2018.12.002</ArticleId><ArticleId IdType="pubmed">30538031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Deng Z., Liu G., Yang J., Zhou W., Zhang C., Shen W., Zhang Y. Platelet-derived extracellular vesicles promote the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes via CXCR2 signaling. Exp. Ther. Med. 2021;22:1&#x2013;8. doi: 10.3892/etm.2021.10554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10554</ArticleId><ArticleId IdType="pmc">PMC8383774</ArticleId><ArticleId IdType="pubmed">34504574</ArticleId></ArticleIdList></Reference><Reference><Citation>Knijff-Dutmer E.A.J., Koerts J., Nieuwland R., Kalsbeek-Batenburg E.M., Van De Laar M.A.F.J. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002;46:1498&#x2013;1503. doi: 10.1002/art.10312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10312</ArticleId><ArticleId IdType="pubmed">12115179</ArticleId></ArticleIdList></Reference><Reference><Citation>Berckmans R.J., Nieuwland R., Tak P.P., B&#xf6;ing A.N., Romijn F., Kraan M.C., Breedveld F.C., Hack C.E., Sturk A. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum. 2002;46:2857&#x2013;2866. doi: 10.1002/art.10587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10587</ArticleId><ArticleId IdType="pubmed">12428225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X. Rac1 regulates platelet microparticles formation and rheumatoid arthritis deterioration. Platelets. 2019;31:112&#x2013;119. doi: 10.1080/09537104.2019.1584669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2019.1584669</ArticleId><ArticleId IdType="pubmed">30880553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P., Fleischmann R., Curtis C., Ignatenko S., Clarke S.H., Desai M., Wong S.L., Grebe K.M., Black K., Zeng J., et al. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus. 2017;27:290&#x2013;302. doi: 10.1177/0961203317719334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317719334</ArticleId><ArticleId IdType="pubmed">28691866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameer M.A., Chaudhry H., Mushtaq J., Khan O.S., Babar M., Hashim T., Zeb S., Tariq M.A., Patlolla S.R., Ali J., et al. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 2022;14:e30330. doi: 10.7759/cureus.30330.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.30330</ArticleId><ArticleId IdType="pmc">PMC9662848</ArticleId><ArticleId IdType="pubmed">36407159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanscombe K.B., Morris D.L., Noble J.A., Dilthey A.T., Tombleson P., Kaufman K.M., Comeau M., Langefeld C.D., Alarcon-Riquelme M.E., Gaffney P.M., et al. Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum. Mol. Genet. 2018;27:3813&#x2013;3824. doi: 10.1093/hmg/ddy280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy280</ArticleId><ArticleId IdType="pmc">PMC6196648</ArticleId><ArticleId IdType="pubmed">30085094</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Tsokos G.C. Gut viruses in the pathogenesis of systemic lupus erythematosus. Sci. Bull. 2023;68:664&#x2013;665. doi: 10.1016/j.scib.2023.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scib.2023.03.017</ArticleId><ArticleId IdType="pubmed">36934010</ArticleId></ArticleIdList></Reference><Reference><Citation>Illescas-Montes R., Corona-Castro C.C., Melguizo-Rodr&#xed;guez L., Ruiz C., Costela-Ruiz V.J. Infectious processes and systemic lupus erythematosus. Immunology. 2019;158:153&#x2013;160. doi: 10.1111/imm.13103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13103</ArticleId><ArticleId IdType="pmc">PMC6797874</ArticleId><ArticleId IdType="pubmed">31386190</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-P&#xe9;rez L., Rojas M., Mu&#xf1;oz-Vahos C., Vanegas-Garc&#xed;a A., V&#xe1;squez G. Plasma microparticles from patients with systemic lupus erythematosus modulate the content of miRNAs in U937 cells. Immunology. 2021;164:253&#x2013;265. doi: 10.1111/imm.13366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13366</ArticleId><ArticleId IdType="pmc">PMC8442235</ArticleId><ArticleId IdType="pubmed">34003488</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobarrez F., Svenungsson E., Pisetsky D.S. Microparticles as autoantigens in systemic lupus erythematosus. Eur. J. Clin. Investig. 2018;48:e13010. doi: 10.1111/eci.13010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13010</ArticleId><ArticleId IdType="pubmed">30062774</ArticleId></ArticleIdList></Reference><Reference><Citation>Plas&#xed;n-Rodr&#xed;guez M.A., Patricio P., Monteagudo J., Garc&#xed;a-Criado A., Cervera R., Reverter J.C., Espinosa G., T&#xe0;ssies D. Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus. J. Thromb. Thrombolysis. 2020;52:30&#x2013;41. doi: 10.1007/s11239-020-02295-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02295-1</ArticleId><ArticleId IdType="pubmed">33011897</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbano C., Villar-Vesga J., Orejuela J., Mu&#xf1;oz C., Vanegas A., V&#xe1;squez G., Rojas M., Casta&#xf1;o D. Potential Involvement of Platelet-Derived Microparticles and Microparticles Forming Immune Complexes during Monocyte Activation in Patients with Systemic Lupus Erythematosus. Front. Immunol. 2018;9:322. doi: 10.3389/fimmu.2018.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00322</ArticleId><ArticleId IdType="pmc">PMC5837989</ArticleId><ArticleId IdType="pubmed">29545790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasse S., Julien A.-S., Duchez A.-C., Zhao C., Boilard E., Fortin P.R., Bourgoin S.G. Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus. Lupus Sci. Med. 2022;9:e000605. doi: 10.1136/lupus-2021-000605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000605</ArticleId><ArticleId IdType="pmc">PMC8905995</ArticleId><ArticleId IdType="pubmed">35260475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen H., Cuadrado M.J., Erkan D., Duarte-Garcia A., Isenberg D.A., Knight J.S., Ortel T.L., Rahman A., Salmon J.E., Tektonidou M.G., et al. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus. 2020;29:1571&#x2013;1593. doi: 10.1177/0961203320950461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320950461</ArticleId><ArticleId IdType="pmc">PMC7658424</ArticleId><ArticleId IdType="pubmed">33100166</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M. Antiphospholipid syndrome. Transl. Res. 2020;225:70&#x2013;81. doi: 10.1016/j.trsl.2020.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.04.006</ArticleId><ArticleId IdType="pmc">PMC7487027</ArticleId><ArticleId IdType="pubmed">32413497</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano A., Cervera R., Gris J.C. Editorial: Primary Antiphospholipid Syndrome. Front. Immunol. 2020;11:1993. doi: 10.3389/fimmu.2020.01993.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01993</ArticleId><ArticleId IdType="pmc">PMC7484724</ArticleId><ArticleId IdType="pubmed">32983139</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil D.N., Gonz&#xe1;lez-Albo I.P., Rosen L., Lillie T., Stacey A., Parfitt L., Soff G.A. A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. Investig. New Drugs. 2023;41:317&#x2013;323. doi: 10.1007/s10637-023-01345-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-023-01345-8</ArticleId><ArticleId IdType="pmc">PMC9999314</ArticleId><ArticleId IdType="pubmed">36897458</ArticleId></ArticleIdList></Reference><Reference><Citation>Akca U.K., Ayaz N.A. Comorbidities of antiphospholipid syndrome and systemic lupus erythematosus in children. Curr. Rheumatol. Rep. 2020;22:21. doi: 10.1007/s11926-020-00899-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00899-3</ArticleId><ArticleId IdType="pubmed">32405806</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;tok U., Blokar E., Lenassi M., Holcar M., Frank-Bertoncelj M., Erman A., Resnik N., Sodin-&#x160;emrl S., &#x10c;u&#x10d;nik S., Pirkmajer K.P., et al. Characterization of Plasma-Derived Small Extracellular Vesicles Indicates Ongoing Endothelial and Platelet Activation in Patients with Thrombotic Antiphospholipid Syndrome. Cells. 2020;9:1211. doi: 10.3390/cells9051211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051211</ArticleId><ArticleId IdType="pmc">PMC7290474</ArticleId><ArticleId IdType="pubmed">32414170</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen K., Sanchez K., Kirkman N., Seed P., Parmar K., Moore G., Hunt B. Endothelial and platelet microparticles in patients with antiphospholipid antibodies. Thromb. Res. 2014;135:368&#x2013;374. doi: 10.1016/j.thromres.2014.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.11.027</ArticleId><ArticleId IdType="pubmed">25496997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Lian Y., Zhang Y., Li L., Li H., Shen D., Zhou Y., Zhang M., Lu Y., Liu J., et al. Platelet-derived microparticles from recurrent miscarriage associated with antiphospholipid antibody syndrome influence behaviours of trophoblast and endothelial cells. Mol. Hum. Reprod. 2019;25:483&#x2013;494. doi: 10.1093/molehr/gaz019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/gaz019</ArticleId><ArticleId IdType="pubmed">30953065</ArticleId></ArticleIdList></Reference><Reference><Citation>Di L., Zha C., Liu Y. Platelet-derived microparticles stimulated by anti-&#x3b2;2GPI/&#x3b2;2GPI complexes induce pyroptosis of endothelial cells in antiphospholipid syndrome. Platelets. 2022;34:2156492. doi: 10.1080/09537104.2022.2156492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2022.2156492</ArticleId><ArticleId IdType="pubmed">36550078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Zhou Q., Yang Y., Li L., Yu M., Li H., Li A., Wang X., Jiang Y. Identification and ultrasensitive photoelectrochemical detection of LncNR_040117: A biomarker of recurrent miscarriage and antiphospholipid antibody syndrome in platelet-derived microparticles. J. Nanobiotechnology. 2022;20:396. doi: 10.1186/s12951-022-01608-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01608-1</ArticleId><ArticleId IdType="pmc">PMC9429728</ArticleId><ArticleId IdType="pubmed">36045427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariette X., Criswell L.A. Primary Sj&#xf6;gren&#x2019;s Syndrome. N. Engl. J. Med. 2018;378:931&#x2013;939. doi: 10.1056/NEJMcp1702514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp1702514</ArticleId><ArticleId IdType="pubmed">29514034</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Pang K., Wang J., Zhang B., Liu Z., Lu S., Xu X., Zhu L., Zhou Z., Niu M., et al. Microbiota dysbiosis in primary Sj&#xf6;gren&#x2019;s syndrome and the ameliorative effect of hydroxychloroquine. Cell Rep. 2022;40:111352. doi: 10.1016/j.celrep.2022.111352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111352</ArticleId><ArticleId IdType="pubmed">36103827</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslinska M., Kostyra-Grabczak K. The role of virus infections in Sj&#xf6;gren&#x2019;s syndrome. Front. Immunol. 2022;13:823659. doi: 10.3389/fimmu.2022.823659.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.823659</ArticleId><ArticleId IdType="pmc">PMC9488556</ArticleId><ArticleId IdType="pubmed">36148238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Ieng F.C., Lai Y.-H. Optic Neuritis and Immune Thrombocytopenia as the Initial Presentation of Primary Sj&#xf6;gren Syndrome. J. Neuro-Ophthalmology. 2021. online ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wno.0000000000001436</ArticleId><ArticleId IdType="pubmed">34924533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellam J., Proulle V., J&#xfc;ngel A., Ittah M., Richard C.M., Gottenberg J.-E., Toti F., Benessiano J., Gay S., Freyssinet J.-M., et al. Increased levels of circulating microparticles in primary Sj&#xf6;gren&#x2019;s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Thromb. Haemost. 2009;11:R156. doi: 10.1186/ar2833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2833</ArticleId><ArticleId IdType="pmc">PMC2787287</ArticleId><ArticleId IdType="pubmed">19832990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoloni E., Alunno A., Bistoni O., Caterbi S., Luccioli F., Santoboni G., Mirabelli G., Cannarile F., Gerli R. Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjogren&#x2019;s syndrome: New markers of chronic endothelial damage? Rheumatology. 2014;54:536&#x2013;544. doi: 10.1093/rheumatology/keu320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu320</ArticleId><ArticleId IdType="pubmed">25190637</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazzei G., van Vollenhoven R.F., de Jong B.A., Siegelaar S.E., van Schaardenburg D. Preclinical Autoimmune Disease: A Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes. Front. Immunol. 2022;13:899372. doi: 10.3389/fimmu.2022.899372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.899372</ArticleId><ArticleId IdType="pmc">PMC9281565</ArticleId><ArticleId IdType="pubmed">35844538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang L., Wu G.-R., Zhou Q., Yue H., Rao L.-Z., Yuan T., Mo B., Wang F.-X., Chen L.-M., et al. MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Sci. Adv. 2021;7:eabb6075. doi: 10.1126/sciadv.abb6075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb6075</ArticleId><ArticleId IdType="pmc">PMC7775789</ArticleId><ArticleId IdType="pubmed">33277324</ArticleId></ArticleIdList></Reference><Reference><Citation>Marou E., Liaskos C., Efthymiou G., Dardiotis E., Daponte A., Scheper T., Meyer W., Hadjigeorgiou G., Bogdanos D.P., Sakkas L.I. Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis. Ann. Rheum. Dis. 2017;35((Suppl. 106)):31&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">28240591</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G., Trier N.H. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front. Immunol. 2021;11:587380. doi: 10.3389/fimmu.2020.587380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587380</ArticleId><ArticleId IdType="pmc">PMC7817975</ArticleId><ArticleId IdType="pubmed">33488588</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna D., Tashkin D.P., Denton C.P., Renzoni E.A., Desai S.R., Varga J. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am. J. Respir. Crit. Care Med. 2020;201:650&#x2013;660. doi: 10.1164/rccm.201903-0563CI.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201903-0563CI</ArticleId><ArticleId IdType="pmc">PMC7068837</ArticleId><ArticleId IdType="pubmed">31841044</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x10c;oli&#x107; J., Cerinic M.M., Guiducci S., Damjanov N. Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question! J. Scleroderma Relat. Disord. 2019;5:6&#x2013;20. doi: 10.1177/2397198319857356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2397198319857356</ArticleId><ArticleId IdType="pmc">PMC8922594</ArticleId><ArticleId IdType="pubmed">35382401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntelis K., Bogdanos D., Dimitroulas T., Sakkas L., Daoussis D. Platelets in Systemic Sclerosis: The Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis? Curr. Rheumatol. Rep. 2019;21:15. doi: 10.1007/s11926-019-0815-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-019-0815-z</ArticleId><ArticleId IdType="pubmed">30830444</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M., Guillotin V., Truchetet M.-E., Contin-Bordes C., Sisirak V., Duffau P., Lazaro E., Richez C., Blanco P. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Autoimmun. Rev. 2018;17:625&#x2013;635. doi: 10.1016/j.autrev.2018.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.01.012</ArticleId><ArticleId IdType="pubmed">29635077</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyabu C., Morinobu A., Sugiyama D., Saegusa J., Tanaka S., Morinobu S., Tsuji G., Kasagi S., Kawano S., Kumagai S. Plasma Platelet-derived Microparticles in Patients with Connective Tissue Diseases. J. Rheumatol. 2011;38:680&#x2013;684. doi: 10.3899/jrheum.100780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100780</ArticleId><ArticleId IdType="pubmed">21239749</ArticleId></ArticleIdList></Reference><Reference><Citation>Leleu D., Levionnois E., Laurent P., Lazaro E., Richez C., Duffau P., Blanco P., Sisirak V., Contin-Bordes C., Truchetet M.-E. Elevated Circulatory Levels of Microparticles Are Associated to Lung Fibrosis and Vasculopathy During Systemic Sclerosis. Front. Immunol. 2020;11:532177. doi: 10.3389/fimmu.2020.532177.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.532177</ArticleId><ArticleId IdType="pmc">PMC7645042</ArticleId><ArticleId IdType="pubmed">33193304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu C., Walia A., Ortiz V., Perry C., Woo S., Reeves B.C., Sun H., Winkler J., Kanyo J.E., Wang W., et al. Bioactive Plasma Mitochondrial DNA Is Associated With Disease Progression in Scleroderma-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2020;72:1905&#x2013;1915. doi: 10.1002/art.41418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41418</ArticleId><ArticleId IdType="pmc">PMC8081728</ArticleId><ArticleId IdType="pubmed">32602227</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredi A.A., Ramirez G.A., Godino C., Capobianco A., Monno A., Franchini S., Tombetti E., Corradetti S., Distler J.H.W., Bianchi M.E., et al. Platelet Phagocytosis via P-selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis. Arthritis Rheumatol. 2021;74:318&#x2013;328. doi: 10.1002/art.41926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41926</ArticleId><ArticleId IdType="pubmed">34279048</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.A., Braun W.E., Kushner I., Grecek D.E., Muir W.A., Steinberg A.G. HLA B27 in Ankylosing Spondylitis: Differences in Frequency and Relative Risk in American Blacks and Caucasians. J. Rheumatol. 2023;50:39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">36587954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Liao Q., Hu Y., Zhong D. T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp. Ther. Med. 2014;9:250&#x2013;256. doi: 10.3892/etm.2014.2046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2014.2046</ArticleId><ArticleId IdType="pmc">PMC4247318</ArticleId><ArticleId IdType="pubmed">25452811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.H., Song G.G. Diabetes mellitus in ankylosing spondylitis. Ann. Rheum. Dis. 2019;80:e142. doi: 10.1136/annrheumdis-2019-216335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216335</ArticleId><ArticleId IdType="pubmed">31615751</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsur A.M., David P., Watad A., Nissan D., Cohen A.D., Amital H. Ankylosing Spondylitis and the Risk of Hip Fractures: A Matched Cohort Study. J. Gen. Intern. Med. 2022;37:3283&#x2013;3288. doi: 10.1007/s11606-021-07241-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-021-07241-2</ArticleId><ArticleId IdType="pmc">PMC9550950</ArticleId><ArticleId IdType="pubmed">35411534</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian H., Chen R., Wang B., Yuan X., Chen S., Liu Y., Shi G. Associations of Platelet Count with Inflammation and Response to Anti-TNF-&#x3b1; Therapy in Patients with Ankylosing Spondylitis. Front. Pharmacol. 2020;11:559593. doi: 10.3389/fphar.2020.559593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.559593</ArticleId><ArticleId IdType="pmc">PMC7741170</ArticleId><ArticleId IdType="pubmed">33343345</ArticleId></ArticleIdList></Reference><Reference><Citation>Sari I., Bozkaya G., Kirbiyik H., Alacacioglu A., Ates H., Sop G., Can G., Taylan A., Piskin O., Yildiz Y., et al. Evaluation of Circulating Endothelial and Platelet Microparticles in Men with Ankylosing Spondylitis. J. Rheumatol. 2012;39:594&#x2013;599. doi: 10.3899/jrheum.111073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.111073</ArticleId><ArticleId IdType="pubmed">22247348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Meng S., Chen P., Wei L., Liu C., Tang D., Liu D., Jiang Z., Hong X. Comprehensive analysis of differentially expressed mRNA and circRNA in Ankylosing spondylitis patients&#x2019; platelets. Exp. Cell Res. 2021;409:112895. doi: 10.1016/j.yexcr.2021.112895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2021.112895</ArticleId><ArticleId IdType="pubmed">34717918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D., Walsh M., Merkel P.A., Peh C.A., Szpirt W., Pu&#xe9;chal X., Fujimoto S., Hawley C., Khalidi N., Jones R., et al. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Health Technol. Assess. 2022;26:1&#x2013;60. doi: 10.3310/PNXB5040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/PNXB5040</ArticleId><ArticleId IdType="pubmed">36155131</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca E., Sandoval P., Burgos P.I. Central Nervous System and Systemic Vasculitis in an Immunocompetent Syphilitic Non-HIV Patient. Am. J. Clin. Oncol. 2020;28:e684&#x2013;e686. doi: 10.1097/RHU.0000000000001572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001572</ArticleId><ArticleId IdType="pubmed">32956152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A., Leierer J., Gauckler P., Shin J.I. Comorbidities in ANCA-associated vasculitis. Rheumatology. 2020;59:iii79&#x2013;iii83. doi: 10.1093/rheumatology/kez617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez617</ArticleId><ArticleId IdType="pmc">PMC7190116</ArticleId><ArticleId IdType="pubmed">32348518</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon C.W., Park H.-K., Rha J.-H. Yield of Screening Tests for Systemic Vasculitis in Young Adults with Ischemic Stroke. Eur. Neurol. 2018;80:245&#x2013;248. doi: 10.1159/000496373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000496373</ArticleId><ArticleId IdType="pubmed">30716738</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogan P.A., Shah V., Brachet C., Harnden A., Mant D., Klein N., Dillon M.J. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum. 2004;50:927&#x2013;936. doi: 10.1002/art.20199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20199</ArticleId><ArticleId IdType="pubmed">15022336</ArticleId></ArticleIdList></Reference><Reference><Citation>Berden A.E., Nolan S.L., Morris H.L., Bertina R.M., Erasmus D.D., Hagen E.C., Hayes D.P., van Tilburg N.H., Bruijn J.A., Savage C.O., et al. Anti-Plasminogen Antibodies Compromise Fibrinolysis and Associate with Renal Histology in ANCA-Associated Vasculitis. J. Am. Soc. Nephrol. 2010;21:2169&#x2013;2179. doi: 10.1681/ASN.2010030274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2010030274</ArticleId><ArticleId IdType="pmc">PMC3014030</ArticleId><ArticleId IdType="pubmed">20847144</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao D., Ma T.-T., Chen M., Zhao M.-H. Platelets release proinflammatory microparticles in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology. 2019;58:1432&#x2013;1442. doi: 10.1093/rheumatology/kez044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez044</ArticleId><ArticleId IdType="pubmed">30843591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada H., Suzuki H., Onouchi Y., Ebata R., Terai M., Fuse S., Okajima Y., Kurotobi S., Hirai K., Soga T., et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): A randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019;393:1128&#x2013;1137. doi: 10.1016/s0140-6736(18)32003-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(18)32003-8</ArticleId><ArticleId IdType="pubmed">30853151</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J., Wang J., Lu Y., Fan Z., Huang N., Ma L., Yu H. Platelet-Derived Microparticles: A New Index of Monitoring Platelet Activation and Inflammation in Kawasaki Disease. Indian J. Pediatr. 2018;86:250&#x2013;255. doi: 10.1007/s12098-018-2765-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12098-018-2765-2</ArticleId><ArticleId IdType="pubmed">30159809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>